New 100 mg/dL Target Glucose setting offers more customization and tighter glucose management. Enhanced algorithm helps users remain in Automated Mode to improve the user experience. Most requested ...

Q1 2026 Management View “We achieved 30% revenue growth, including 28% in the U.S. and 45% internationally,” and “we are raising our full year 2026 total company revenue growth guidance from 20% to 22 ...

(RTTNews) - Insulet (PODD) announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. The new 100 mg/dL Target Glucose expands ...

Insulet Corporation PODD recently received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new ...

In 2024, Insulet shared results from its landmark SECURE-T2D pivotal trial, demonstrating improved glycemic outcomes with Omnipod 5 compared with prior insulin injection or pump therapy in adults with ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its ...

The expanded approval for the Omnipod 5 system now allows automated insulin delivery (AID) for adults with type 2 diabetes, offering a new option for better glucose management without daily injections ...